Have you been asked to switch from a biologic  medicine to a new biosimilar? Here we have some useful information for everyone who wants to know more.

When your doctor, nurse or specialist wants to talk to you about changing your medication it is natural to  want to understand the reasons why. Some patients  are being asked to 'switch' from biological medicines to biosimilar medicines, but do you know the difference?

For the past year, the Patients Association has been working with patients, clinicians and pharmacists to create a suite of resources to help you understand why you might be asked to switch to biosimilar medication, what biosimilars are, and how the switch should work for you. We also encourage you to ask questions, whether you are talking  to your doctor, nurse or specialist, and provide you with details of specialist organisations should you need more specific help and information.

Resources

Please download and read our leaflet on biosimilars here.  

You can watch our information video below (or click here to watch with subtitles).

Further information

If you want to find out more about biosimilars, you might find the following list of organisations useful.
(The Patients Association is not responsible for information on external sites)


NHS
Information on biosimilars

National Rheumatoid Arthritis Society (NRAS)
Information on biosimilars
Helpline: 0800 298 7650
Email: [email protected]

Crohns and Colitis UK
Information on biosimilar drugs for adalimumab (Humira)
Helpline: 0300 222 5700
Email: [email protected]s.org.uk

Birdshot Uveitis Society (BUS)
Biosimilars to Humira (adalimumab) - Q&As
Email: [email protected]

The Psoriasis Association
psoriasis-association.org.uk
Tel: 01604 251 620
Email: [email protected]

Diabetes UK
Diabetes UK statement on biosimilar insulin
Tel: 0345 123 2399
Email: [email protected]

JDRF (Type 1 diabetes charity)
jdrf.org.uk information on biosimilar insulin (published September 2015)
Tel: 020 7713 2030
Email: [email protected]

National Ankylosing Spondylitis Society (NASS)
NASS biosimilar information
Helpline: 020 8741 1515

Lymphoma Action
Information on biosimilar lymphoma medication
Helpline: 0808 808 5555
Email: [email protected]

The Switching to Biosimilars project has been developed by the Patients Association, supported through sponsorship from Novo Nordisk and Amgen, and an unrestricted educational grant from Sanofi. No companies had any influence on the development of the materials but they have commented on the final versions.